COVAXIN® production volumes ramped up by Bharat Biotech, by additional 200 million 

by Suman Gupta

Hyderabad, India, May 2021: Bharat Biotech a global leader in vaccine innovation, developing vaccines for infectious diseases, announced today, the quick ramp up of additional manufacturing capacities for COVAXIN^®, India’s 1st Indigenous Covid 19 Vaccine at CHIRON BEHRING Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech.

The company plans to produce 200 million doses of COVAXIN^® per annum in the good manufacturing practice (GMP) facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety. Product availability at Ankleshwar to commence from Q4 2021.

Bharat Biotech had already deployed multiple Production lines at its Hyderabad & Bengaluru campuses, Adding Chiron Behring to this line up of high containment BSL rated GMP facilities that are required to manufacture COVAXIN^®. This effectively takes the volumes upto ~ 1 Billion doses per Annum, with its own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety.

About Bharat Biotech:Bharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 123 countries, and the World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution.

Having delivered close to 5 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis (JENVAC®), Rabies, Chikungunya, Zika, Cholera, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid. Bharat’s commitment to global social innovation programs and public-private partnerships resulted in introducing path-breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC®, and Typbar TCV® combatting polio, rotavirus, typhoid infections, respectively. The acquisition of Chiron Behring Vaccines, has positioned Bharat Biotech as the world’s largest rabies vaccine manufacturer with Chirorab® and Indirab®.

To learn more about Bharat Biotech, visithttp://www.bharatbiotech.com.

About CHIRON BEHRING:Chiron Behring Vaccines Pvt Ltd, located in Ankleshwar, Gujarat is a 100% subsidiary of Bharat Biotech International Limited. Chiron Behring Vaccines was formed as a result of the purchase of the vaccines business of Hoechst AG by Chiron Corporation USA. It is one of the largest manufacturers of high-quality rabies vaccines in the world. Chiron Behring Vaccines is a WHO Pre-qualified manufacturer of rabies vaccines, eligible for supplies to UN agencies and has product registrations in more than 20 countries. Acquiring of Chiron Behring Vaccines Pvt Ltd has established Bharat Biotech as a global leader in rabies vaccines manufacturer.